Anti - Mouse, CD79a Clone JCB117
- Known as:
- Anti - Mouse, CD79a Clone JCB117
- Catalog number:
- 61-0095-2
- Product Quantity:
- 0.2mL
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- Anti - Mouse CD79a Clone JCB117
Related genes to: Anti - Mouse, CD79a Clone JCB117
- Gene:
- CD79A NIH gene
- Name:
- CD79a molecule
- Previous symbol:
- IGA
- Synonyms:
- MB-1
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-07-31
- Date modifiied:
- 2019-04-23
Related products to: Anti - Mouse, CD79a Clone JCB117
Related articles to: Anti - Mouse, CD79a Clone JCB117
- Although IFI44 is recognized for its crucial role in autoimmune disorders, its function in breast cancer (BC) remains unclear. This study aimed to investigate the immune-related and prognostic significance of IFI44 in BC. - Source: PubMed
Publication date: 2026/04/08
Wu JiahuiYi WangLiu MengtingLi YingliangZhou BoxuanWu ZiyunCao WeiShi QingfengCai XiangkaiXiong Haiwei - This report describes a diagnostically challenging case of B-cell acute lymphoblastic leukemia (B-ALL) perfectly mimicking multifocal Langerhans cell histiocytosis (LCH), revealing a critical diagnostic pitfall in pediatric oncology. - Source: PubMed
Xiao DejunLiao HongPeng FangWen XinglinLiu Zhiqing - Accurate identification and spatial enumeration of B lineage cells in formalin-fixed, paraffin-embedded (FFPE) lupus nephritis (LN) kidney tissue is critical for understanding disease pathogenesis and CD20-directed therapeutic responses. We developed a targeted 5-plex immunofluorescence and digital image analysis workflow for simultaneous enumeration of B cells, plasma cells (PCs), and plasmablasts (PBs) in FFPE human tissues that is amenable to deployment in LN clinical trials. We validated this workflow on two tonsils and eight LN biopsy tissue blocks. Comparison of B lineage markers confirmed that CD79a provides far superior sensitivity for interstitial B cells compared to CD19, establishing it as the requisite anchor for B cell burden assessment in FFPE lupus nephritis tissue. Accordingly, B cells were defined as CD79a/CD138; PCs as CD138/CD38/Ki-67; and PBs as CD138/CD38/Ki-67. These definitions ensured unambiguous cell classifications, overcoming the challenge of variable CD138 expression in renal tubular epithelium. Whole slide analysis of LN tissues revealed comparable average frequencies of B cells versus PCs (~250 cells/mm), with far fewer PBs (~14 cells/mm). Comparison with an exploratory "permissive" gating strategy (CD38/Ki-67) confirmed the absence of CD138 B-lineage plasmablasts, validating the sufficiency of CD138 for tissue ASC enumeration. Most PCs and PBs were CD79a, indicating the retention of a functional B-cell program that may contribute to disease pathogenesis. This robust, validated, fit-for-purpose methodology is poised for deployment in larger clinical LN cohorts to evaluate local tissue impacts of B-cell depletion therapies, deepening our understanding of disease pathogenesis and treatment responses. - Source: PubMed
Publication date: 2026/03/25
Chan CalebChang Patrick SChalasani SreedeviTao JanetRaghu HariniAustin Cary D - Primary central nervous system lymphoma (PCNSL) often presents with ocular involvement that mimics benign inflammatory conditions, frequently delaying diagnosis. We report a case of a 41-year-old healthy woman presenting with diminished vision and floaters. Examination revealed panuveitis with characteristic hypopigmented retinal lesions exhibiting a 'leopard-skin' pattern. Despite the absence of systemic symptoms and a vitreous sample of low cellularity, diagnostic pars plana vitrectomy confirmed large B-cell lymphoma via immunophenotyping (CD20, CD79a and PAX5). Subsequent magnetic resonance imaging (MRI) demonstrated a parieto-occipital brain mass. The patient received high-dose methotrexate-based chemotherapy according to the DeAngelis protocol, combined with rituximab, selected to optimise disease control while minimising the neurotoxicity associated with whole-brain radiotherapy. She achieved visual recovery to 6/9 and regression of the central nervous system (CNS) lesion. This case underscores the importance of recognising pathognomonic retinal signs and employing molecular immunophenotyping to enable timely, life-saving, neuro-sparing therapy. - Source: PubMed
Publication date: 2026/03/06
Goh Sue-ZianNg Kwang-ShengWan Hitam Wan-HazabbahSuparmaniam SrubanNordin Mohammad Hudzaifah - Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of methotrexate-associated lymphoma arising in immune deficiency/dysregulation (MTX-associated IDD-DLBCL) among rheumatoid arthritis patients treated with MTX and is characterized by frequent spontaneous regression (SR) after MTX withdrawal. However, some patients do not achieve SR and have poor outcomes. Epstein-Barr virus (EBV) infection correlates with frequent SR but does not fully explain clinical heterogeneity. We investigated prognostic factors irrespective of EBV infection status. We analyzed 21 MTX-associated IDD-DLBCL cases applying the nCounter PanCancer Immune Profiling Panel and immunohistochemistry (IHC) to identify predictors of non-SR cases. Ten patients were classified as SR and 11 as non-SR. Gene expression profiling revealed higher expression of CD83, ICOSLG, IL21R, BCL6, CD40, PAX5, CXCR5, CD79A, DMBT1, and TNFRSF13C in non-SR cases. We therefore focused on CD83, which showed the highest fold change and the most significant P value among these markers. Although CD83 is reported to be a surface marker of mature dendritic cells, IHC analysis revealed that CD83 was more frequently expressed on tumor cells than on dendritic cells. High CD83 IHC positivity (≥15%) in tumor cells correlated with mRNA levels and predicted non-SR after MTX withdrawal. Multivariate analysis identified CD83 IHC high expression as an independent predictor of non-SR cases. High CD83 expression is an independent prognostic factor in MTX-associated IDD-DLBCL, and combined evaluation may refine risk stratification and guide clinical decisions. - Source: PubMed
Sawada KeisukeTakahashi TakumiFukumura YukiOnagi HirokoAshizawa KarinYamashita TakahisaYamamoto WataruTakayanagi NatsukoAdachi AkikoKashimura MakotoTabayashi TakayukiTamaru Jun-IchiHigashi MorihiroMomose Shuji